---
schema_version: "secwatch.filing_event.v1"
accession: "0001093557-25-000264"
form_type: "8-K"
ticker: "DXCM"
cik: "0001093557"
company_name: "DEXCOM INC"
filed_at: "2025-10-27T23:59:59+00:00"
generated_at: "2026-05-17T02:08:33.766640+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Dexcom appoints Dr. Euan Ashley to board; board size expanded to 11 in 2026

## Summary
- Appointed Euan Ashley, M.D., to Board effective Oct 24, 2025; board size increased to 10 then to 11 effective Jan 1, 2026.
- Ashley chairs Stanford Dept. of Medicine, co-founded 7 biotech firms, brings clinical and AI/digital health expertise.
- Received initial RSU grant of $500k vesting over 3 years; eligible for annual director equity grant of $345k.
- Appointed to Nominating and Governance Committee and Technology Committee; Kyle Malady steps down from Nominating but remains Tech chair.

## SEC filing metadata
- accession: 0001093557-25-000264
- form_type: 8-K
- ticker: DXCM
- cik: 0001093557
- company_name: DEXCOM INC
- filed_at: 2025-10-27T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1093557/000109355725000264/0001093557-25-000264-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1093557/000109355725000264/dxcm-20251024.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001093557-25-000264
- JSON: https://secwatch.observer/filing/0001093557-25-000264.json
- Plain text: https://secwatch.observer/filing/0001093557-25-000264.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.